SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2014 / Cilt: 44 - Sayı: 1

PUVA phototherapy-induced secondary amyloidosis in patients with mycosis fungoides: a rare adverse effect of phototherapy Itır

Ebru ZEMHERİ
İlkin ZİNDANCI
Serkan ŞENOL
Filiz DEMİR2TOPALOĞLU
Özge AKBULAK
Sıdıka Şeyma ÖZKANLI
Pages
89–94
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: It should be noted that secondary amyloidosis can be present in patients who have been treated with PUVA therapy and it can be a result of the apoptotic effect of PUVA on the basal keratinocytes.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Amyloidosis is a common disorder in adults.
📊
Key Findings & Data:Secondary amyloidosis in patients with mycosis fungoides (MF) after photochemotherapy with 8-methoxypsoralen followed by ultraviolet A (PUVA) treatment has not been reported.
💡
Conclusion & Impact:Conclusion: It should be noted that secondary amyloidosis can be present in patients who have been treated with PUVA therapy and it can be a result of the apoptotic effect of PUVA on the basal keratinocytes.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Amyloidosis is a common disorder in adults. Secondary amyloidosis in patients with mycosis fungoides (MF) after photochemotherapy with 8-methoxypsoralen followed by ultraviolet A (PUVA) treatment has not been reported. Our aim is to describe the clinical and histological features of PUVA phototherapy-induced secondary amyloidosis. Materials and methods: Sixty-one patients with MF treated with PUVA phototherapy were analyzed clinically and pathologically and by staining with Congo red and crystal violet. Results: Of 61 patients, 5 met the study criteria. Secondary amyloidosis was detected in 5 patients treated with PUVA. The secondary amyloidosis appeared after a mean of 56 exposures (range: 30 81) and a mean cumulative PUVA radiation dose of 131.7 J/cm2 (range: 31 305.5). The mean follow-up duration from the date of occurrence of the secondary amyloidosis was 18.2 weeks (range: 10 30). Histologically, vacuolar interface changes, colloid bodies, and melanophages were seen in all 5 patients. There were 4 patients who had perivascular lymphocytic infiltration and 1 patient had lichenoid lymphocytic infiltration. Conclusion: It should be noted that secondary amyloidosis can be present in patients who have been treated with PUVA therapy and it can be a result of the apoptotic effect of PUVA on the basal keratinocytes.

🔖

Cite This Article

ZEMHERİ, E., ZİNDANCI, İ., ŞENOL, S., DEMİR2TOPALOĞLU, F., AKBULAK, Ö., ÖZKANLI, S. Ş. (2022). PUVA phototherapy-induced secondary amyloidosis in patients with mycosis fungoides: a rare adverse effect of phototherapy Itır. Turkish Journal of Medical Sciences, Cilt: 44 - Sayı: 1, 89–94. https://ajindex.com/articles/610979

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Baron ED, Stevens SR. Phototherapy for cutaneous T-cell lymphoma. Dermatol Ther 2003; 16: 303–10
  2. Morita A, Werfel T, Stege H, Ahrens C. Evidence that singlet oxygen-induced human T-helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy. J Exp Med 1997; 186: 1763–8
  3. Nasser N, Sassevılle D. Amyloidosis. Dermatol Rounds 2005; 4: 3
  4. Buxbaum JN, Tagoe CE. The genetics of the amyloidoses. Ann Rev Med 2000; 51: 543–69
  5. Picken MM. The changing concepts of amyloid. Arch Pathol Lab Med 2001; 125: 38–43
  6. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997; 337: 898–909
  7. Schreml S, Szeimies RM, Vogt T, Landthaler M, Schroeder J, Babilas P. Cutaneous amyloidoses and systemic amyloidoses with cutaneous involvement Eur J Dermatol 2010; 20: 152–60
  8. Breathnach SM. Amyloid and amyloidosis. J Am Acad Dermatol 1988; 18: 1–16
  9. Glenner GG. Amyloid deposits and amyloidosis. The betafibrilloses (first of two parts). N Engl J Med 1980; 302: 1283–92
  10. Kumakiri M, Hashimoto K. Histogenesis of primary localized cutaneous amyloidosis: sequential change of epidermal keratinocytes to amyloid via filamentous degeneration. J Invest Dermatol 1979; 73: 150–62
  11. Li WM. Histopathology of primary cutaneous amyloidoses and systemic amyloidosis. Clin Dermatol 1990; 8: 30–5
  12. Brownstein MH, Helwig EB. Secondary systemic amyloidosis: analysis of the underlying disorders. South Med J 1971; 64: 491–6
  13. Hashimoto K, Brownstein MH. Localized amyloidosis in basal cell epitheliomas. Acta Derm Venereol 1973; 53: 331–9
  14. Hashimoto K, Kumakiri M. Colloid-amyloid bodies in PUVAtreated human psoriatic patients. J Invest Dermatol 1979; 72: 70–80
  15. MacDonald DM, Black MM. Secondary localized cutaneous amyloidosis in melanocytic naevi. Br J Dermatol 1980; 103: 553–6
  16. Powell AM, Albert S, Bhogal B, Black MM. Discoid lupus erythematosus with secondary amyloidosis. Br J Dermatol 2005; 153: 746–9
  17. Ramírez-Santos A, Suárez-Amor O, Pérez-Pérez L, Loureiro M, Peteiro C, Toribio J. Localized cutaneous amyloidosis secondary to porokeratosis: a retrospective histopathologic study of 30 patients. Actas Dermosifiliogr 2008; 99: 639–43 (article in Spanish with English abstract)
  18. Johansen JD, Frosch PJ, Lepoıttenvın JP. Contact Dermatitis. Berlin: Springer; 2011. p.155–62 19. Dall’Acqua F, Vedaldi D, Bordin F, Rodighiero G. New studies on the interaction between 8-methoxypsoralen and DNA in vitro.